treated the wild-type and PPM1D-mutant AML cell line Molm13 with the antimetabolite cytarabine and assessed the effects of the specific PPM1D inhibitor GSK2830371 in these cells (Kahn et al., 2018). This evidence concerns the gene PPM1D and acute myeloid leukemia.